CN112689508A - 减少或治疗胰岛素抗性和代谢病状的组合物和方法 - Google Patents

减少或治疗胰岛素抗性和代谢病状的组合物和方法 Download PDF

Info

Publication number
CN112689508A
CN112689508A CN201980054586.0A CN201980054586A CN112689508A CN 112689508 A CN112689508 A CN 112689508A CN 201980054586 A CN201980054586 A CN 201980054586A CN 112689508 A CN112689508 A CN 112689508A
Authority
CN
China
Prior art keywords
amino acid
composition
acid entity
entity
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054586.0A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈米尔
瑞弗·亚非恩
李中伟
哈利·路易特哈特
威廉·康柏
纳丁·道尔
斯维特拉娜·马鲁基安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CN112689508A publication Critical patent/CN112689508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980054586.0A 2018-06-20 2019-06-19 减少或治疗胰岛素抗性和代谢病状的组合物和方法 Pending CN112689508A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862687727P 2018-06-20 2018-06-20
US62/687,727 2018-06-20
US201962794134P 2019-01-18 2019-01-18
US62/794,134 2019-01-18
PCT/US2019/038037 WO2019246299A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions

Publications (1)

Publication Number Publication Date
CN112689508A true CN112689508A (zh) 2021-04-20

Family

ID=67185732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054586.0A Pending CN112689508A (zh) 2018-06-20 2019-06-19 减少或治疗胰岛素抗性和代谢病状的组合物和方法

Country Status (6)

Country Link
US (2) US20210275479A1 (https=)
EP (1) EP3810122A1 (https=)
JP (1) JP2021527671A (https=)
CN (1) CN112689508A (https=)
MA (1) MA52953A (https=)
WO (1) WO2019246299A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679774A (zh) * 2024-11-15 2025-03-25 北京体育大学 预防或治疗代谢性疾病的药物及应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
CN111514276B (zh) * 2020-06-29 2021-07-27 黑龙江中医药大学 短肽Asp-His-Tyr在制备治疗多囊卵巢综合征的药物中的应用
WO2022266480A1 (en) * 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
WO2023009444A1 (en) 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
EP4643658A1 (en) * 2024-04-29 2025-11-05 Laboratorios Ern S.A. Dietary product for hypoproteic diet

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557301A (zh) * 2004-01-15 2004-12-29 高春平 降低老年肥胖型糖尿病人血糖和血脂的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTOFFER CLEMMENSEN, ET AL.: "Oral L-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice", 《ENDOCRINOLOGY》, pages 3978 *
JUNPING ZHENG，ET AL.: "N-Acetyl-Cysteine Alleviates Gut Dysbiosis and Glucose Metabolic Disorder in High-Fat Diet-Induced Mice，Running title: Effect of N-Acetyl-Cysteine on Gut Dysbiosis", 《JOURNAL OF DIABETES》, pages 32 - 45 *
LAVIGNE C ET AL: "COD AND SOY PROTEINS CDMPARED WITH CASEIN IMPROVE GLUC0SE T0LERANCE AND INSULIN SENSITIVITY IN RATS", 《AMERICAN JOURNAL 0F PHYSIOLOGY:ENDOCRIN0L0GY AND METABOLISM》, pages 491 - 102 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679774A (zh) * 2024-11-15 2025-03-25 北京体育大学 预防或治疗代谢性疾病的药物及应用

Also Published As

Publication number Publication date
US20240238232A1 (en) 2024-07-18
US20210275479A1 (en) 2021-09-09
MA52953A (fr) 2021-04-28
EP3810122A1 (en) 2021-04-28
WO2019246299A1 (en) 2019-12-26
JP2021527671A (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
US20240041810A1 (en) Amino acid compositions and methods for the treatment of liver diseases
CN112689508A (zh) 减少或治疗胰岛素抗性和代谢病状的组合物和方法
TWI775921B (zh) 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法
AU2008329988A1 (en) Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition
CN112839712A (zh) 用于减少或治疗发炎的组合物和方法
US20210275480A1 (en) Compositions and methods for the reduction or treatment of fibrosis
OA19827A (en) Amino acid compositions and methods for the treatment of liver diseases.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210420